Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
monoclonal antibody Ch14.18
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II Study of MOAB Ch14.18 with GM-CSF for Recurrent Neuroblastoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
under 21
Sponsor:
NCI
Protocol IDs:
POG-9347
2.
Phase I Study of Monoclonal Antibody Ch14.18 Combined With Sargramostim (GM-CSF) and Interleukin-2 After Autologous Bone Marrow or Peripheral Blood Stem Cell Rescue in Children With Neuroblastoma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
COG-A0935A
, CCG-0935, CCG-0935A, NCT00005576
3.
Phase I Study of Monoclonal Antibodies Ch14.18 and R24 with IL-2 for Melanoma, Small Cell Lung Carcinoma, Soft Tissue Sarcoma, and Other GD2- and GD3-Positive Tumors (Summary Last Modified 09/97)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
WCCC-CO-9391
, NCI-B94-0002, B94-0002
4.
Phase Ia/Ib Study of Chimeric Monoclonal Anti-GD2 Antibody 14.18 in Patients with Metastatic Melanoma (Summary Last Modified 06/93)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Protocol IDs:
UAB-185
, NCI-B89-0005, B89-0005
5.
Phase I Study of Melanoma-Reactive Chimeric Anti-GD-2 Monoclonal Antibody 14.18 plus IL-2 for Refractory Metastatic Melanoma (Summary Last Modified 11/94)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Protocol IDs:
WCCC-CO-9097
, NCI-B90-0014, B90-0014
6.
Phase I Study of Chimeric MOAB 14.18 plus GM-CSF for Metastatic Melanoma (Summary Last Modified 05/95)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 to physiologic 70
Sponsor:
Protocol IDs:
MDA-DM-90102
, NCI-B93-0009, B93-0009
7.
Phase I Pilot Study of Chimeric MOAB 14.18 for Refractory Small Cell Lung Cancer (Summary Last Modified 03/97)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-93049A4
, NCI-B93-0001, B93-0001
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute